CLRB (Cellectar Biosciences) Accumulated Depreciation: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLRB Cellectar Biosciences Inc CLRB
25 GF Score
Price $2.60
! 1 Warning Sign
View Full Analysis

What is Cellectar Biosciences Accumulated Depreciation?

Cellectar Biosciences CLRB +4.84% 25 Accumulated Depreciation is $0.00 Mil as of Jun. 2026. GuruFocus rates CLRB with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Cellectar Biosciences's quarterly accumulated depreciation declined from Dec. 2025 ($-1.19 Mil) to Mar. 2026 ($0.00 Mil) but then stayed the same from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($0.00 Mil).

Cellectar Biosciences's annual accumulated depreciation increased from Dec. 2023 ($-0.89 Mil) to Dec. 2024 ($-1.02 Mil) and increased from Dec. 2024 ($-1.02 Mil) to Dec. 2025 ($-1.19 Mil).

Cellectar Biosciences Accumulated Depreciation Related Terms

Cellectar Biosciences Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Cellectar Biosciences's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectar Biosciences Accumulated Depreciation Chart

Cellectar Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.55 -0.69 -0.89 -1.02 -1.19

Cellectar Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1.19 0.00 0.00
CLRB
25GF Score
Cellectar Biosciences Inc CLRB
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectar Biosciences Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $0.00 Mil mean?
Cellectar Biosciences (CLRB) has a Accumulated Depreciation of $0.00 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Cellectar Biosciences and its competitors.
Is Cellectar Biosciences' Accumulated Depreciation too high?
Cellectar Biosciences' current Accumulated Depreciation is $0.00 Mil. Overall, Cellectar Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cellectar Biosciences' Accumulated Depreciation compare to DARE and NEUP?
Cellectar Biosciences' Accumulated Depreciation of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Cellectar Biosciences and its competitors. Cellectar Biosciences's current Accumulated Depreciation is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectar Biosciences stock overvalued right now?
Cellectar Biosciences (CLRB) has a current Accumulated Depreciation of $0.00 Mil. The current Accumulated Depreciation is $0.00 Mil. Cellectar Biosciences' overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Cellectar Biosciences (CLRB), the current Accumulated Depreciation is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cellectar Biosciences Business Description

Address 100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
25GF Score

Get the complete analysis for CLRB

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.60
Price